NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $1.18 -0.15 (-10.90%) Closing price 03:59 PM EasternExtended Trading$1.19 +0.00 (+0.42%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Autolus Therapeutics Stock (NASDAQ:AUTL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Autolus Therapeutics alerts:Sign Up Key Stats Today's Range$1.18▼$1.3350-Day Range$1.14▼$2.0752-Week Range$1.11▼$5.00Volume1.93 million shsAverage Volume1.43 million shsMarket Capitalization$315.32 millionP/E RatioN/ADividend YieldN/APrice Target$9.32Consensus RatingBuy Company OverviewAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More… Autolus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreAUTL MarketRank™: Autolus Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 650th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAutolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.79% of the float of Autolus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 15.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.79% of the float of Autolus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 15.54%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News Sentiment1.33 News SentimentAutolus Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Autolus Therapeutics this week, compared to 3 articles on an average week.Search Interest13 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.MarketBeat Follows4 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Stock News HeadlinesAutolus Therapeutics’ obecabtagene autoleucel conditionally approved by MHRAApril 27, 2025 | markets.businessinsider.comAutolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRAApril 26, 2025 | finance.yahoo.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.May 6, 2025 | Paradigm Press (Ad)UK approves Autolus leukemia therapy with conditionsApril 26, 2025 | investing.comAutolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)April 25, 2025 | globenewswire.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | finance.yahoo.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | globenewswire.comAutolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 22, 2025 | globenewswire.comSee More Headlines AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $2.35 on January 1st, 2025. Since then, AUTL stock has decreased by 49.6% and is now trading at $1.1850. View the best growth stocks for 2025 here. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) announced its earnings results on Thursday, March, 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $2.98 million. Read the conference call transcript. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Top institutional shareholders of Autolus Therapeutics include Perpetual Ltd (0.46%), Cetera Investment Advisers (0.20%), Hennion & Walsh Asset Management Inc. (0.15%) and Alps Advisors Inc. (0.08%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings3/20/2025Today5/06/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUTL CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$9.32 High Stock Price Target$13.00 Low Stock Price Target$6.00 Potential Upside/Downside+673.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-208,380,000.00 Net MarginsN/A Pretax Margin-2,677.50% Return on Equity-63.65% Return on Assets-36.54% Debt Debt-to-Equity RatioN/A Current Ratio13.69 Quick Ratio13.69 Sales & Book Value Annual Sales$10.12 million Price / Sales31.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.88Miscellaneous Outstanding Shares266,094,000Free Float197,708,000Market Cap$320.64 million OptionableOptionable Beta1.77 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:AUTL) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.